Registry follows treatment and outcomes in advanced pancreatic cancer in Austria
Collects real-world data on treatments and outcomes in adults with advanced pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Key facts
- Where
- Amstetten, Feldkirch, Graz, Innsbruck, Klagenfurt, Linz, Salzburg, Sankt Pölten, Vienna, and Zams, AustriaSee the 14 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which describes how well you can do daily activities?
Source: NCT05526443, who can take part
Where in Austria
- Landesklinikum AmstettenAmstetten, AustriaTaking people
- Landesklinikum FeldkirchFeldkirch, AustriaTaking people
- Krankenhaus der Barmherzigen BrüderGraz, AustriaTaking people
- Medical University Graz Department of OncologyGraz, AustriaTaking people
- Universitätsklinikum InnsbruckInnsbruck, AustriaTaking people
- Landesklinikum KlagenfurtKlagenfurt, AustriaTaking people
- Kepler University HospitalLinz, AustriaTaking people
- Ordensklinikum LinzLinz, AustriaTaking people
- Salzburg State Hospital, PMU University ClinicSalzburg, AustriaTaking people
- Universitätsklinikum St. PöltenSankt Pölten, AustriaTaking people
- Barmherzige Schwestern Krankenhaus WienVienna, AustriaTaking people
- Pancreatic Cancer Unit des Comprehensive Cancer Center (CCC-PCU)Vienna, AustriaTaking people
- St. Josef Krankenhaus WienVienna, AustriaTaking people
- Krankenhaus St. Vinzenz ZamsZams, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Graz
- Trial code
- NCT05526443
- Record updated
- 1 September 2026
- Original description
To systematically collect and analyse real-world data on treatment patterns, clinical outcomes and toxicities among patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systematic treatment in AustriaRead full original descriptionShow less
Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
To systematically collect and analyse real-world data on treatment patterns, clinical outcomes and toxicities among patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systematic treatment in Austria
Inclusion: 18 years, female and male; ECOG (Eastern Cooperative Oncology Group) Scale 0-2; Diagnosis of histologically confirmed locally advanced inoperable and/or metastatic PDAC; Patients undergoing palliative 1st line therapy with a platinum- or gemcitabine- based chemotherapy in case of previous (neo)adjuvant therapy also patients who receive nal-Irinotecan/5-FU/Leukovorin as palliative first line are eglible; Signed informed consent for prospective patients, for retrospective cases no informed consent is required.
Exclusion: Patients with locally advanced operable PDAC who do not receive palliative chemotherapy; Patients with locally advanced borderline resectable PDAC who do not receive palliative chemotherapy.